Neutralization of Hepatitis C Virus (HCV)
In Hepatitis C Virus (HCV), there exists a pair of antibody binding sites; one that binds to a neutralizing antibody, called the neutralizing epitope or epitope I, and one that binds to an interfering antibody which in turn interferes with the binding of the neutralizing antibody, called the interfering epitope or epitope II. This invention describes a method and composition which has uses for treating or preventing HCV infections. The invention is directed to an HCV E2 polypeptide substitution of native amino acids LFY in epitope II and to HCV E2 polypeptide deletion of native amino acids LFY in epitope II. The invention is also directed to an HCV E2 polypeptide insertion of amino acids between the native LFY in epitope II. This allows attenuation or disabling of the interference effect of HCV-E2 epitope II. By introducing a mutation in the interfering epitope and depleting the interfering antibodies, the composition is thus enriched with HCV neutralizing antibodies. This composition can be used to improve the immune response to HCV infection in vaccine or immunotherapeutic products or to enhance neutralizing activity of immune globulin.
Potential Commercial Applications:
- Used for improved HCV Vaccines
- Used to prevent HCV infections in patients with known exposure (e.g. stick with a contaminated hypodermic needle)
- Used as an inhibitor to block the binding of interfering antibody in a patient with HCV infection and improve binding of the neutralizing antibody
- Generate a unique product that can be used for post exposure prophylaxis
- Generate the first effective vaccine for HCV
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
OTT Reference No: E-276-2007/1
Updated: September 22, 2015